New Five-Drug cocktail targets tough myeloma
NCT ID NCT07600151
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study tests a new five-drug combination for people newly diagnosed with high-risk multiple myeloma. The goal is to see if adding two extra drugs (etentamig and isatuximab) to a standard three-drug regimen improves outcomes. About 220 participants will receive the combo before and after a stem cell transplant. The study checks safety and how well the treatment controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.